JTCS Speed Up Your Browser
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sharath, M. D.
Right arrow Articles by Weiler, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sharath, M. D.
Right arrow Articles by Weiler, J. M.

The Journal of Thoracic and Cardiovascular Surgery, Vol 90, 86-90, Copyright © 1985 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Protamine-induced fatal anaphylaxis. Prevalence of antiprotamine immunoglobulin E antibody

MD Sharath, WJ Metzger, HB Richerson, RK Scupham, RL Meng, BH Ginsberg and JM Weiler

Protamine is used widely to reverse the anticoagulant effects of heparin and to delay the absorption of insulin. Although adverse reactions to protamine are reported infrequently and are usually mild, we recently observed the first fatal case of type I anaphylaxis resulting from protamine. This patient had previously been sensitized to protamine during cardiac catheterization and had high levels of protamine-specific immunoglobulin E in the serum. In a prospective study, we found that 10 of 19 diabetic patients (53%) who had received insulin containing insulin also had high levels of antiprotamine immunoglobulin E. In contrast, none of 27 nondiabetic healthy normal controls or 10 diabetics who had never received protamine or protamine- containing insulin had levels of antiprotamine immunoglobulin E over background. This study underscores the risks of routinely administering protamine to susceptible individuals and the need for alternative therapies.


This article has been cited by other articles:


Home page
 ChestHome page
J. Milot, J. Perron, Y. Lacasse, L. Letourneau, P. C. Cartier, and F. Maltais
Incidence and Predictors of ARDS After Cardiac Surgery
Chest, March 1, 2001; 119(3): 884 - 888.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
S. E. Kimmel, M. A. Sekeres, J. A. Berlin, N. Ellison, V. J. DiSesa, and B. L. Strom
Risk factors for clinically important adverse events after protamine administration following cardiopulmonary bypass
J. Am. Coll. Cardiol., December 1, 1998; 32(7): 1916 - 1922.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. Hirsh and J. Hoak
Management of Deep Vein Thrombosis and Pulmonary Embolism : A Statement for Healthcare Professionals From the Council on Thrombosis (in Consultation With the Council on Cardiovascular Radiology), American Heart Association
Circulation, June 15, 1996; 93(12): 2212 - 2245.
[Full Text]

Home page
 PerfusionHome page
J. H Levy
Review article : Anaphylactic reactions during cardiac surgery
Perfusion, January 1, 1991; 6(1): 3 - 13.
[PDF]

Home page
 PerfusionHome page
A T. Pezzella, A. Ascioti, and P. Ricardi
Noncardiogenic pulmonary oedema following cardiopulmonary bypass: report of two cases and review of the literature
Perfusion, January 1, 1988; 3(1): 21 - 28.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1985 by The American Association for Thoracic Surgery.